{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:29:26Z","timestamp":1787873366133,"version":"build-2784847793"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.14310\/horm.2002.1757","type":"journal-article","created":{"date-parts":[[2018,2,11]],"date-time":"2018-02-11T23:35:42Z","timestamp":1518392142000},"page":"373-380","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Prevalence, pathogenesis and management of prediabetes and type 2 diabetes mellitus in patients with polycystic ovary syndrome"],"prefix":"10.1007","volume":"16","author":[{"given":"Sofia","family":"Lazaridou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Dinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Tziomalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,30]]},"reference":[{"key":"16040373_CR1","first-page":"3078","volume":"83","author":"ES Knochenhauer","year":"1998","unstructured":"Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R, 1998 Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83: 3078\u20133082.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR2","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1210\/jcem.84.11.6148","volume":"84","author":"E Diamanti-Kandarakis","year":"1999","unstructured":"Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al, 1999 A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 84: 4006\u20134011.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR3","first-page":"19","volume":"81","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group","year":"2004","unstructured":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group, 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81: 19\u201325.","journal-title":"Fertil Steril"},{"key":"16040373_CR4","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","volume":"91","author":"R Azziz","year":"2009","unstructured":"Azziz R, Carmina E, Dewailly D, et al, 2009 Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society: the Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91: 456\u2013488.","journal-title":"Fertil Steril"},{"key":"16040373_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/humupd\/dmq001","volume":"16","author":"LJ Moran","year":"2010","unstructured":"Moran LJ, Misso ML, Wild RA, Norman RJ, 2010 Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 16: 347\u2013363.","journal-title":"Hum Reprod Update"},{"key":"16040373_CR6","first-page":"165","volume":"84","author":"RS Legro","year":"1999","unstructured":"Legro RS, Kunselman AR, Dodson WC, Dunaif A, 1999 Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84: 165\u2013169.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR7","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1210\/jc.2005-2430","volume":"91","author":"JC Lo","year":"2006","unstructured":"Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS, 2006 Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 91: 1357\u20131363.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1089\/jwh.2006.0098","volume":"16","author":"EO Talbott","year":"2007","unstructured":"Talbott EO, Zborowski JV, Rager JR, Kip KE, Xu X, Orchard TJ, 2007 Polycystic ovarian syndrome (PCOS): a significant contributor to the overall burden of type 2 diabetes in women. J Womens Health (Larchmt) 16: 191\u2013197.","journal-title":"J Womens Health (Larchmt)"},{"key":"16040373_CR9","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.2337\/dc08-0423","volume":"31","author":"ES Ford","year":"2008","unstructured":"Ford ES, Li C, Sattar N, 2008 Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 31: 1898\u20131904.","journal-title":"Diabetes Care"},{"key":"16040373_CR10","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1093\/humrep\/den263","volume":"23","author":"AJ Cussons","year":"2008","unstructured":"Cussons AJ, Watts GF, Burke V, Shaw JE, Zimmet PZ, Stuckey BG, 2008 Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum Reprod 23: 2352\u20132358.","journal-title":"Hum Reprod"},{"key":"16040373_CR11","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/cen.12008","volume":"78","author":"D Panidis","year":"2013","unstructured":"Panidis D, Macut D, Tziomalos K, et al, 2013 Prevalence of metabolic syndrome in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 78: 586\u2013592.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"16040373_CR12","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1093\/humrep\/det255","volume":"28","author":"E Lerchbaum","year":"2013","unstructured":"Lerchbaum E, Schwetz V, Giuliani A, Obermayer-Pietsch B, 2013 Assessment of glucose metabolism in polycystic ovary syndrome: HbA1c or fasting glucose compared with the oral glucose tolerance test as a screening method. Hum Reprod 28: 2537\u20132544.","journal-title":"Hum Reprod"},{"key":"16040373_CR13","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/humrep\/det002","volume":"28","author":"C Celik","year":"2013","unstructured":"Celik C, Abali R, Bastu E, Tasdemir N, Tasdemir UG, Gul A, 2013 Assessment of impaired glucose tolerance prevalence with hemoglobin A1c and oral glucose tolerance test in 252 Turkish women with polycystic ovary syndrome: a prospective, controlled study. Hum Reprod 28: 1062\u20131068.","journal-title":"Hum Reprod"},{"key":"16040373_CR14","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/humrep\/16.9.1995","volume":"16","author":"RJ Norman","year":"2001","unstructured":"Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ, 2001 Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 16: 1995\u20131998.","journal-title":"Hum Reprod"},{"key":"16040373_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11892-006-0056-1","volume":"6","author":"MY Boudreaux","year":"2006","unstructured":"Boudreaux MY, Talbott EO, Kip KE, Brooks MM, Witchel SF, 2006 Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up. Curr Diab Rep 6: 77\u201383.","journal-title":"Curr Diab Rep"},{"key":"16040373_CR16","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1210\/jc.2004-1843","volume":"90","author":"RS Legro","year":"2005","unstructured":"Legro RS, Gnatuk CL, Kunselman AR, Dunaif A, 2005 Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 90: 3236\u20133242.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR17","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.2337\/db11-1360","volume":"61","author":"A Gambineri","year":"2012","unstructured":"Gambineri A, Patton L, Altieri P, et al, 2012 Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study. Diabetes 61: 2369\u20132374.","journal-title":"Diabetes"},{"key":"16040373_CR18","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1210\/jc.2012-1690","volume":"97","author":"CL Morgan","year":"2012","unstructured":"Morgan CL, Jenkins-Jones S, Currie CJ, Rees DA, 2012 Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: a retrospective, observational study. J Clin Endocrinol Metab 97: 3251\u20133260.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.fertnstert.2004.01.041","volume":"82","author":"E Carmina","year":"2004","unstructured":"Carmina E, Lobo RA, 2004 Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 82: 661\u2013665.","journal-title":"Fertil Steril"},{"key":"16040373_CR20","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.fertnstert.2004.11.070","volume":"83","author":"CM DeUgarte","year":"2005","unstructured":"DeUgarte CM, Bartolucci AA, Azziz R, 2005 Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 83: 1454\u20131460.","journal-title":"Fertil Steril"},{"key":"16040373_CR21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2298\/VSP0206593M","volume":"59","author":"D Macut","year":"2002","unstructured":"Macut D, Micic D, Parapid B, et al, 2002 Age and body mass related changes of cardiovascular risk factors in women with polycystic ovary syndrome. Vojnosanit Pregl 59: 593\u2013599.","journal-title":"Vojnosanit Pregl"},{"key":"16040373_CR22","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.fertnstert.2011.11.041","volume":"97","author":"D Panidis","year":"2012","unstructured":"Panidis D, Tziomalos K, Macut D, et al, 2012 Cross-sectional analysis of the effects of age on the hormonal, metabolic, and ultrasonographic features and the prevalence of the different phenotypes of polycystic ovary syndrome. Fertil Steril 97: 494\u2013500.","journal-title":"Fertil Steril"},{"key":"16040373_CR23","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.2337\/diab.38.9.1165","volume":"38","author":"A Dunaif","year":"1989","unstructured":"Dunaif A, Segal KR, Futterweit W, Dobrjansky A, 1989 Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38: 1165\u20131174.","journal-title":"Diabetes"},{"key":"16040373_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.diabres.2017.06.011","volume":"130","author":"D Macut","year":"2017","unstructured":"Macut D, Bjeki\u0107-Macut J, Raheli\u0107 D, Dokni\u0107 M, 2017 Insulin and the polycystic ovary syndrome. Diabetes Res Clin Pract 130: 163\u2013170.","journal-title":"Diabetes Res Clin Pract"},{"key":"16040373_CR25","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/humrep\/des463","volume":"28","author":"NK Stepto","year":"2013","unstructured":"Stepto NK, Cassar S, Joham AE, et al, 2013 Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod 28: 777\u2013784.","journal-title":"Hum Reprod"},{"key":"16040373_CR26","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1093\/humrep\/dew243","volume":"31","author":"S Cassar","year":"2016","unstructured":"Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ, Stepto NK, 2016 Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod 31: 2619\u20132631.","journal-title":"Hum Reprod"},{"key":"16040373_CR27","first-page":"1241","volume":"76","author":"NM O\u2019Meara","year":"1993","unstructured":"O\u2019Meara NM, Blackman JD, Ehrmann DA, et al, 1993 Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 76: 1241\u20131247.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR28","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1093\/humrep\/12.9.1897","volume":"12","author":"M Ciampelli","year":"1997","unstructured":"Ciampelli M, Fulghesu AM, Cucinelli F, et al, 1997 Heterogeneity in beta cell activity, hepatic insulin clearance and peripheral insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 12: 1897\u20131901.","journal-title":"Hum Reprod"},{"key":"16040373_CR29","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.2337\/diacare.25.7.1217","volume":"25","author":"J Vrb\u00edkov\u00e1","year":"2002","unstructured":"Vrb\u00edkov\u00e1 J, Bendlov\u00e1 B, Hill M, Vankov\u00e1 M, Vondra K, St\u00e1rka L, 2002 Insulin sensitivity and beta-cell function in women with polycystic ovary syndrome. Diabetes Care 25: 1217\u20131222.","journal-title":"Diabetes Care"},{"key":"16040373_CR30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1210\/jc.2007-1834","volume":"93","author":"BO Yildiz","year":"2008","unstructured":"Yildiz BO, Knochenhauer ES, Azziz R, 2008 Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 93: 162\u2013168.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR31","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1210\/jc.2006-2725","volume":"92","author":"E Carmina","year":"2007","unstructured":"Carmina E, Bucchieri S, Esposito A, et al, 2007 Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab 92: 2500\u20132505.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2337\/diacare.22.1.141","volume":"22","author":"DA Ehrmann","year":"1999","unstructured":"Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J, 1999 Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22: 141\u2013146.","journal-title":"Diabetes Care"},{"key":"16040373_CR33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/09513590802585597","volume":"25","author":"JJ Espin\u00f3s-G\u00f3mez","year":"2009","unstructured":"Espin\u00f3s-G\u00f3mez JJ, Corcoy R, Calaf J, 2009 Prevalence and predictors of abnormal glucose metabolism in Mediterranean women with polycystic ovary syndrome. Gynecol Endocrinol 25:199\u2013204.","journal-title":"Gynecol Endocrinol"},{"key":"16040373_CR34","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1210\/js.2017-00323","volume":"1","author":"JM Boumosleh","year":"2017","unstructured":"Boumosleh JM, Grundy SM, Phan J, Neeland IJ, Chang A, Vega GL, 2017 Metabolic Concomitants of Obese and Nonobese Women With Features of Polycystic Ovarian Syndrome. J Endocr Soc 1: 1417\u20131427.","journal-title":"J Endocr Soc"},{"key":"16040373_CR35","first-page":"8","volume":"2016","author":"D Scott","year":"2016","unstructured":"Scott D, Joham A, Teede H, et al, 2016 Associations of Vitamin D with Inter- and Intra-Muscular Adipose Tissue and Insulin Resistance in Women with and without Polycystic Ovary Syndrome. Nutrients 2016: 8.pii:E774.","journal-title":"Nutrients"},{"key":"16040373_CR36","doi-asserted-by":"publisher","first-page":"4842","DOI":"10.1210\/jc.2006-1327","volume":"91","author":"CK Welt","year":"2006","unstructured":"Welt CK, Gudmundsson JA, Arason G, et al, 2006 Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab 91: 4842\u20134848.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR37","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/humrep\/den433","volume":"24","author":"AJ Goverde","year":"2009","unstructured":"Goverde AJ, van Koert AJ, Eijkemans MJ, et al, 2009 Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum Reprod 24: 710\u2013717.","journal-title":"Hum Reprod"},{"key":"16040373_CR38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/humrep\/der418","volume":"27","author":"D Panidis","year":"2012","unstructured":"Panidis D, Tziomalos K, Misichronis G, et al, 2012 Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod 27: 541\u2013549.","journal-title":"Hum Reprod"},{"key":"16040373_CR39","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1677\/joe.1.07070","volume":"192","author":"A Corbould","year":"2007","unstructured":"Corbould A, 2007 Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J Endocrinol 192: 585\u2013594.","journal-title":"J Endocrinol"},{"key":"16040373_CR40","first-page":"265","volume":"79","author":"KH Polderman","year":"1994","unstructured":"Polderman KH, Gooren LJ, Asscheman H, Bakker A, Heine RJ, 1994 Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 79: 265\u2013271.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR41","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1093\/humrep\/13.10.2706","volume":"13","author":"E Dahlgren","year":"1998","unstructured":"Dahlgren E, Landin K, Krotkiewski M, Holm G, Janson PO, 1998 Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 13: 2706\u20132711.","journal-title":"Hum Reprod"},{"key":"16040373_CR42","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1365-2265.2004.01973.x","volume":"60","author":"A Gambineri","year":"2004","unstructured":"Gambineri A, Pelusi C, Genghini S, et al, 2004 Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 60: 241\u2013249.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"16040373_CR43","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1210\/jc.2005-2250","volume":"91","author":"A Gambineri","year":"2006","unstructured":"Gambineri A, Patton L, Vaccina A, et al, 2006 Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab 91: 3970\u20133980.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR44","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1530\/EJE-13-1035","volume":"170","author":"E Lerchbaum","year":"2014","unstructured":"Lerchbaum E, Schwetz V, Giuliani A, Obermayer-Pietsch B, 2014 Influence of a positive family history of both type 2 diabetes and PCOS on metabolic and endocrine parameters in a large cohort of PCOS women. Eur J Endocrinol 170: 727\u2013739.","journal-title":"Eur J Endocrinol"},{"key":"16040373_CR45","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1210\/jc.2005-1494","volume":"91","author":"JM Vink","year":"2006","unstructured":"Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI, 2006 Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab 91: 2100\u20132104.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR46","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1136\/jmedgenet-2011-100427","volume":"49","author":"MO Goodarzi","year":"2012","unstructured":"Goodarzi MO, Jones MR, Li X, et al, 2012 Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. J Med Genet 49: 90\u201395.","journal-title":"J Med Genet"},{"key":"16040373_CR47","doi-asserted-by":"publisher","first-page":"E185","DOI":"10.1210\/jc.2012-2471","volume":"98","author":"P Mutharasan","year":"2013","unstructured":"Mutharasan P, Galdones E, Pe\u00f1alver Bernab\u00e9 B, et al, 2013 Evidence for chromosome 2p16.3 polycystic ovary syndrome susceptibility locus in affected women of European ancestry. J Clin Endocrinol Metab 98: E185\u201390.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR48","doi-asserted-by":"publisher","first-page":"E1342","DOI":"10.1210\/jc.2011-3478","volume":"97","author":"CK Welt","year":"2012","unstructured":"Welt CK, Styrkarsdottir U, Ehrmann DA, et al, 2012 Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry. J Clin Endocrinol Metab 97: E1342\u20131347.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR49","doi-asserted-by":"publisher","first-page":"R11","DOI":"10.1530\/REP-14-0499","volume":"150","author":"AS de Melo","year":"2015","unstructured":"de Melo AS, Dias SV, Cavalli Rde C, et al, 2015 Pathogenesis of polycystic ovary syndrome: multifactorial assessment from the foetal stage to menopause. Reproduction 150: R11\u201324.","journal-title":"Reproduction"},{"key":"16040373_CR50","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.metabol.2017.04.014","volume":"73","author":"C Stefanaki","year":"2017","unstructured":"Stefanaki C, Peppa M, Mastorakos G, Chrousos GP, 2017 Examining the gut bacteriome, virome, and mycobiome in glucose metabolism disorders: Are we on the right track? Metabolism 73: 52\u201366.","journal-title":"Metabolism"},{"issue":"12","key":"16040373_CR51","doi-asserted-by":"publisher","first-page":"e0168390","DOI":"10.1371\/journal.pone.0168390","volume":"2017","author":"L Lindheim","year":"2017","unstructured":"Lindheim L, Bashir M, M\u00fcnzker J, et al, 2017 Alterations in Gut Microbiome Composition and Barrier Function Are Associated with Reproductive and Metabolic Defects in Women with Polycystic Ovary Syndrome (PCOS): A Pilot Study. PLoS One 2017;12:e0168390.","journal-title":"PLoS One"},{"key":"16040373_CR52","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1210\/js.2017-00192","volume":"1","author":"M Cree-Green","year":"2017","unstructured":"Cree-Green M, Rahat H, Newcomer BR, et al, 2017 Insulin Resistance, Hyperinsulinemia, and Mitochondria Dysfunction in Nonobese Girls With Polycystic Ovarian Syndrome. J Endocr Soc 1: 931\u2013944.","journal-title":"J Endocr Soc"},{"key":"16040373_CR53","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.4158\/EP15748.DSCPT2","volume":"21","author":"NF Goodman","year":"2015","unstructured":"Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E; American Association of Clinical Endocrinologists (AACE); 2015 American College of Endocrinology (ACE); Androgen Excess and PCOS Society. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome \u2014 part 2. Endocr Pract 21: 1415\u20131426.","journal-title":"Endocr Pract"},{"key":"16040373_CR54","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-14-0253","volume":"171","author":"G Conway","year":"2014","unstructured":"Conway G, Dewailly D, Diamanti-Kandarakis E, et al, 2014 ESE PCOS Special Interest Group. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol 171: P1\u201329.","journal-title":"Eur J Endocrinol"},{"key":"16040373_CR55","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.fertnstert.2011.07.002","volume":"96","author":"WW Hurd","year":"2011","unstructured":"Hurd WW, Abdel-Rahman MY, Ismail SA, Abdellah MA, Schmotzer CL, Sood A, 2011 Comparison of diabetes mellitus and insulin resistance screening methods for women with polycystic ovary syndrome. Fertil Steril 96: 1043\u20131047.","journal-title":"Fertil Steril"},{"key":"16040373_CR56","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1210\/jc.2013-2350","volume":"98","author":"RS Legro","year":"2013","unstructured":"Legro RS, Arslanian SA, Ehrmann DA, et al, Endocrine Society, 2013 Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 98: 4565\u20134592.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR57","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1210\/jc.2009-2724","volume":"95","author":"RA Wild","year":"2010","unstructured":"Wild RA, Carmina E, Diamanti-Kandarakis E, et al, 2010 Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 95: 2038\u20132049.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR58","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.metabol.2014.07.007","volume":"63","author":"AM Goss","year":"2014","unstructured":"Goss AM, Chandler-Laney PC, Ovalle F, et al, 2014 Effects of a eucaloric reduced-carbohydrate diet on body composition and fat distribution in women with PCOS. Metabolism 63: 1257\u20131264.","journal-title":"Metabolism"},{"key":"16040373_CR59","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1210\/jc.2008-0751","volume":"93","author":"RL Thomson","year":"2008","unstructured":"Thomson RL, Buckley JD, Noakes M, Clifton PM, Norman RJ, Brinkworth GD, 2008 The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 93: 3373\u20133380.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR60","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1093\/humrep\/deq254","volume":"25","author":"S Palomba","year":"2010","unstructured":"Palomba S, Falbo A, Giallauria F, et al, 2010 Six weeks of structured exercise training and hypocaloric diet increases the probability of ovulation after clomiphene citrate in overweight and obese patients with polycystic ovary syndrome: a randomized controlled trial. Hum Reprod 25: 2783\u20132791.","journal-title":"Hum Reprod"},{"key":"16040373_CR61","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/cen.12305","volume":"80","author":"D Panidis","year":"2014","unstructured":"Panidis D, Tziomalos K, Papadakis E, et al, 2014 The role of orlistat combined with lifestyle changes in the management of overweight and obese patients with polycystic ovary syndrome. Clin Endocrinol (Oxf) 80: 432\u2013438.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"16040373_CR62","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1210\/jc.2006-2794","volume":"92","author":"C Vigorito","year":"2007","unstructured":"Vigorito C, Giallauria F, Palomba S, et al, 2007 Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 92: 1379\u20131384.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR63","doi-asserted-by":"publisher","first-page":"E48","DOI":"10.1210\/jc.2010-0828","volume":"96","author":"SK Hutchison","year":"2011","unstructured":"Hutchison SK, Stepto NK, Harrison CL, Moran LJ, Strauss BJ, Teede HJ, 2011 Effects of exercise on insulin resistance and body composition in overweight and obese women with and without polycystic ovary syndrome. J Clin Endocrinol Metab 96: E48\u201356.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR64","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","volume":"344","author":"J Tuomilehto","year":"2001","unstructured":"Tuomilehto J, Lindstr\u00f6m J, Eriksson JG, et al, 2001 Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343\u20131350.","journal-title":"N Engl J Med"},{"key":"16040373_CR65","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, et al, 2002 Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393\u2013403.","journal-title":"N Engl J Med"},{"key":"16040373_CR66","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1210\/jc.2013-2385","volume":"98","author":"JP Domecq","year":"2013","unstructured":"Domecq JP, Prutsky G, Mullan RJ, et al, 2013 Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis. J Clin Endocrinol Metab 98: 4655\u20134663.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR67","doi-asserted-by":"publisher","first-page":"559","DOI":"10.14310\/horm.2002.1444","volume":"12","author":"E Koiou","year":"2013","unstructured":"Koiou E, Tziomalos K, Katsikis I, Delkos D, Tsourdi EA, Panidis D, 2013 Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome. Hormones (Athens) 12: 559\u2013566.","journal-title":"Hormones (Athens)"},{"key":"16040373_CR68","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1093\/humrep\/dem271","volume":"22","author":"B Trolle","year":"2007","unstructured":"Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF, 2007 Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Hum Reprod 22: 2967\u20132973.","journal-title":"Hum Reprod"},{"key":"16040373_CR69","first-page":"139","volume":"85","author":"P Moghetti","year":"2000","unstructured":"Moghetti P, Castello R, Negri C, et al, 2000 Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85: 139\u2013146.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR70","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/humupd\/dmn043","volume":"15","author":"AE Nieuwenhuis-Ruifrok","year":"2009","unstructured":"Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, Middleton P, Norman RJ, 2009 Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. Hum Reprod Update 15: 57\u201368.","journal-title":"Hum Reprod Update"},{"key":"16040373_CR71","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1210\/jc.2004-0176","volume":"90","author":"V Jayagopal","year":"2005","unstructured":"Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL, 2005 Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J Clin Endocrinol Metab 90: 729\u2013733.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"16040373_CR72","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2337\/dc17-S011","volume":"40","author":"American Diabetes Association","year":"2017","unstructured":"American Diabetes Association, 2017 8. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care 40: Suppl 1: 64\u201374.","journal-title":"Diabetes Care"},{"key":"16040373_CR73","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1365-2265.2010.03917.x","volume":"74","author":"XJ Li","year":"2011","unstructured":"Li XJ, Yu YX, Liu CQ, et al, 2011 Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis. Clin Endocrinol (Oxf) 74: 332\u2013339.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"16040373_CR74","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1093\/humrep\/deg343","volume":"18","author":"CJ Glueck","year":"2003","unstructured":"Glueck CJ, Moreira A, Goldenberg N, Sieve L, Wang P, 2003 Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 18: 1618\u20131625.","journal-title":"Hum Reprod"},{"key":"16040373_CR75","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1210\/jc.2008-0115","volume":"93","author":"K Elkind-Hirsch","year":"2008","unstructured":"Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R, 2008 Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 93: 2670\u20132678.","journal-title":"J Clin Endocrinol Metab"},{"key":"16040373_CR76","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/EJE-13-0797","volume":"170","author":"M Jensterle Sever","year":"2014","unstructured":"Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A, 2014 Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol 170: 451\u2013459.","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"16040373_CR77","doi-asserted-by":"publisher","first-page":"114","DOI":"10.2337\/dc17-S016","volume":"40","author":"American Diabetes Association","year":"2017","unstructured":"American Diabetes Association, 2017 13. Management of diabetes in pregnancy. Diabetes Care 40: Suppl 1: 114\u2013119.","journal-title":"Diabetes Care"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.14310\/horm.2002.1757.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.14310\/horm.2002.1757\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.14310\/horm.2002.1757.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T15:40:36Z","timestamp":1739115636000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.14310\/horm.2002.1757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["16040373"],"URL":"https:\/\/doi.org\/10.14310\/horm.2002.1757","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"1 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}